Regina M. Paglia - Jun 1, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: Chief Human Resources Officer
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Stock symbol: DRNA
Transactions as of: Jun 1, 2021
Transactions value $: -$79,786
Form type: 4
Date filed: 6/3/2021, 09:35 PM
Next filing: Jun 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$57.3K	+4.43K		$12.93	4.43K	Jun 1, 2021	Direct
transaction	DRNA	Common Stock	Sale	-$127K	-4.13K	-93.12%	$30.86	305	Jun 1, 2021	Direct	F1, F2, F3
transaction	DRNA	Common Stock	Sale	-$9.75K	-305	-100%	$31.97	0	Jun 1, 2021	Direct	F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-4.43K	-3.47%	$0.00	123K	Jun 1, 2021	Common Stock	4.43K	$12.93	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person sold an aggregate of 4,431 shares of Common Stock on June 1, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.57% of 282,595 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2020.
F3	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.25, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.93 to $32.61, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5	The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.